These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 15715968)
41. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272 [TBL] [Abstract][Full Text] [Related]
42. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990 [TBL] [Abstract][Full Text] [Related]
43. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Kimura Y; Sumiyoshi M; Baba K Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770 [TBL] [Abstract][Full Text] [Related]
44. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Rahimi N Exp Eye Res; 2006 Nov; 83(5):1005-16. PubMed ID: 16713597 [TBL] [Abstract][Full Text] [Related]
45. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977 [TBL] [Abstract][Full Text] [Related]
46. Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Lin CM; Chang H; Chen YH; Li SY; Wu IH; Chiu JH Int Immunopharmacol; 2006 Nov; 6(11):1690-8. PubMed ID: 16979123 [TBL] [Abstract][Full Text] [Related]
47. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193 [TBL] [Abstract][Full Text] [Related]
48. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Anisimov A; Leppänen VM; Tvorogov D; Zarkada G; Jeltsch M; Holopainen T; Kaijalainen S; Alitalo K Sci Signal; 2013 Jul; 6(282):ra52. PubMed ID: 23821770 [TBL] [Abstract][Full Text] [Related]
49. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Lacal PM; Ruffini F; Pagani E; D'Atri S Int J Oncol; 2005 Dec; 27(6):1625-32. PubMed ID: 16273219 [TBL] [Abstract][Full Text] [Related]
50. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Boyer SJ Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Guo XN; Zhong L; Zhang XH; Zhao WM; Zhang XW; Lin LP; Ding J Biochim Biophys Acta; 2004 Aug; 1673(3):186-93. PubMed ID: 15279890 [TBL] [Abstract][Full Text] [Related]
52. Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation. Yan W; Huang Z; Wang Z; Cao S; Tong L; Zhang T; Wang C; Zhou L; Ding J; Luo C; Zhou J; Xie H; Duan W Chem Biol Drug Des; 2016 May; 87(5):694-703. PubMed ID: 26669707 [TBL] [Abstract][Full Text] [Related]
53. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Stewart M; Turley H; Cook N; Pezzella F; Pillai G; Ogilvie D; Cartlidge S; Paterson D; Copley C; Kendrew J; Barnes C; Harris AL; Gatter KC Histopathology; 2003 Jul; 43(1):33-9. PubMed ID: 12823710 [TBL] [Abstract][Full Text] [Related]
54. VEGFR-2 conformational switch in response to ligand binding. Sarabipour S; Ballmer-Hofer K; Hristova K Elife; 2016 Apr; 5():e13876. PubMed ID: 27052508 [TBL] [Abstract][Full Text] [Related]
55. Discovering small molecule ligands of vascular endothelial growth factor that block VEGF-KDR binding using label-free microarray-based assays. Landry JP; Fei Y; Zhu X; Ke Y; Yu G; Lee P Assay Drug Dev Technol; 2013 Jun; 11(5):326-32. PubMed ID: 23772553 [TBL] [Abstract][Full Text] [Related]